- Eli Lilly and Co LLY Phase 3 DINAMO study reached its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with Jardiance (empagliflozin) compared with placebo in children and adolescents with type 2 diabetes.
- When Jardiance was added to other baseline treatments (diet, exercise, metformin and/or insulin), HbA1c was reduced by 0.84% at week 26 compared to placebo.
- Related: Eli Lilly is best-in-class growth, says analyst as he initiates coverage.
- The overall safety data were generally consistent with previous results in adults with type 2 diabetes and confirmed the well-established safety profile of Jardiance and Tradjenta.
- A secondary endpoint of the study showed that Jardiance reduced fasting plasma glucose levels at week 26.
- The reduction in HbA1c in subjects treated with Tradjenta was not statistically significant compared to placebo. A numerical reduction of 0.34% (P=0.2935) was observed.
- Last month, Boehringer Ingelheim and Eli Lilly said Jardiance slows the progression of chronic kidney disease.
- The companies said the EMPA-KIDNEY Phase 3 study met its primary endpoint by demonstrating significant renal and cardiovascular disease Advantage in chronic kidney disease.
- Price promotion: LLY shares are up 1.10% at last check Wednesday to $372.36.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
